Stapled BH3 Peptides against MCL-1: Mechanism and Design Using Atomistic Simulations

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Joseph, Thomas L ^a   Lane, David P ^b   Verma, Chandra S ^a,c,d  

^a BIOINFORMATICS INSTITUTE   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; PROTEIN MCL 1; PROTEIN MDM2; PROTEIN P53; STAPLED BH3 PEPTIDE; UNCLASSIFIED DRUG;

ALPHA HELIX; ARTICLE; ATOM; BINDING AFFINITY; CELL CYCLE; CRYSTAL STRUCTURE; HYDROPHOBICITY; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; PROTEIN PROTEIN INTERACTION;

AMINO ACID SEQUENCE; DRUG DESIGN; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, SECONDARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SOLUTIONS;

EID: 84865630184     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043985     Document Type: Article

References (76)

1. Thompson C, (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462.
2. Czerski L, Nunez G, (2004) Apoptosome formation and caspase activation: is it different in the heart? J Mol Cell Cardiol 37: 643-652.
3. Wilk S, (2005) Apoptosis. Sci STKE 285: tr16.
4. Youle RJ, Strasser A, (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59.
5. Gross A, Mc Donnell J, Korsmeyer SJ, (1999) BCL-2 family members and the mitochondriain apoptosis. Genes and Development 13: 1899-1911.
6. Michels J, Johnson P, Packham G, (2005) Mcl-1. Int J Biochem & Cell Biol 37: 267-271.
7. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW, (1993) MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Pro Nat Aca Sci U S A 90: 3516-3520.
8. Germain M, Nguyen A, Le Grand JN, Arbour N, Vanderluit JL, et al. (2010) MCL-1 is a stress sensor that regulates autophagy in a developmentally regulated manner. EMBO J 30: 395-407.
9. Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, et al. (2005) Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 19: 1248-1252.
10. Simonian PL, Grillot D, Nunez G, (1997) Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 90: 1208-1216.
11. Quinn BA, Dash R, Azab B, Sarkar S, Das SK, et al. (2011) Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 20: 1397-1411.
12. Azmi AS Wang Z, Philip PA, Mohammad RM, Sarkar FH (2011) Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs 16: 59-70.
13. Yang T, Kozopas K, Craig RW, (1995) The intra cellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to those of Bcl-2. J Cell Biol 128: 1173-1184.
14. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, et al. (2003) Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes and Development 17: 1475-1486.
15. Craig RW, (2002) MCL-1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tunorigenesis. Leukemia 16: 444-454.
16. Cuconati A, Mukherjee C, Perez D, White E, (2003) DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes and Development 17: 2922-2932.
17. Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, et al. (2010) The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 52: 1310-1321.
18. Oltersdorf T, Elmore S, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
19. Bernardo PH, Sivaraman T, Wan KF, Xu J, Krishnamoorthy J, et al. (2010) Structural insights into the design of small molecule inhibitors that selectively antagonize Mcl-1. J Med Chem 53: 2314-2318.
20. Nguyen MM, Richard C, Roulston A, Watson M, Serfass L, et al. (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 104: 19512-19517.
21. Lessene G, Czabotar P, Colman PM, (2008) BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discovery 7: 989-1000.
22. Zhai D, Jin C, Satterthwait AC, Reed JC, (2006) Comparison of chemical inhibitors of antiapoptotic Bcl-2 family proteins. Cell Death Differ 13: 1419-1421.
23. Dutta S, Gulla S, Chen TS, Fire E, Grant RA, et al. (2010) Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL J Mol Biol. 398: 747-762.
24. Stewart ML, Fire E, Keating AE, Walensky LD, (2010) The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 6: 595-601.
25. Walensky LD, Kung A, Escher I, Malia TJ, Barbuto S, et al. (2004) Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305: 1466-1470.
26. Joseph TL, Lane DP, Verma CS, (2010) Stapled peptides in the p53 pathway: computer simulations reveal novel interactions of the staples with the target protein. Cell Cycle 9: 4560-4568.
27. Cheok CF, Verma CS, Baselga J, Lane DP, (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8: 25-37.
28. Schafmeister CE, Julia P, Verdine GL, (2000) An All-Hydrocarbon Cross-Linking System for Enhancing the Helicity and Metabolic Stability of Peptides J Am Chem Soc. 122: 5891-5892.
29. Wolfson W, (2009) Aileron staples peptides. Chem Biol Drug Des 16: 910-912.
30. Kim YW, Verdine GL, (2009) Stereochemical effects of all-hydrocarbon tethers in i,i+4 stapled peptides. Bioorg Med Chem Lett 19: 2533-2536.
31. Walensky L, (2012) From Mitochondrial Biology to Magic Bullet: Navitoclax Disarms BCL-2 in Chronic Lymphocytic Leukemia. J Clin Oncol 30: 554-557.
32. Bernal F, Tyler A, Korsmeyer SJ, Walensky LD, Verdine GL, (2007) Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc 129: 2456-2457.
33. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, et al. (2009) Direct inhibition of the NOTCH transcription factor complex. Nature 462: 182-188.
34. Phillips C, Roberts LR, Schade M, Bazin R, Bent A, et al. (2011) Design and Structure of Stapled Peptides Binding to Estrogen Receptors. J Am Chem Soc 133: 9696-9699.
35. Sviridov DO, Ikpot IZ, Stonik J, Drake SK, Amar M, et al. (2011) Helix stabilization of amphipathic peptides by hydrocarbon stapling increases cholesterol efflux by the ABCA1 transporter. Biochem Biophys Res Commun 410: 446-451.
36. Bhattacharya S, Zhang H, Debnath AK, Cowburn D, (2008) Solution Structure of a Hydrocarbon Stapled Peptide Inhibitor in Complex with Monomeric C-terminal Domain of HIV-1 Capsid. J Biol Chem 283: 16274-16278.
37. Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG,et al. (2010) Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci U S A 107: 14093-14098.
38. Baek S, Kutchukian PS, Verdine GL, Huber R, Holak TA, et al. (2012) Structure of the Stapled p53 Peptide Bound to Mdm2. J Am Chem Soc 134: 103-106.
39. Boehr DD, Nussinov R, Wright PE, (2009) The role of dynamic conformational ensembles in biomolecular recognition Nat Chem Biol. 5: 789-796.
40. Joseph TL, Madhumalar A, Brown CJ, Lane DP, Verma C, (2010) Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies. Cell Cycle 9: 167-181.
41. Dastidar SG, Lane D, Verma CS, (2008) Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J Am Chem Soc 130: 13514-13515.
42. Sali A, Blundell TL, (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779-815.
43. Liu Q, Moldoveanu T, Sprules T, Matta-Camacho E, Mansur-Azzam N, et al. (2010) Apoptotic regulation by MCL-1 through heterodimerization. J Biol Chem 285: 19615-19624.
44. Case DA, Datten TA, Cheatham III TE, Simmerling CL, Wang J, et al. (2006) AMBER 9. University of California, San Francisco.
45. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA, (2004) Development and testing of a general AMBER force field. J Comput Chem 25: 1157-1174.
46. Wang J, Wang W, Kollman PA, Case DA, (2006) Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model 25: 247-260.
47. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz Jr KM, et al. (1995) A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 117: 5179-5197.
48. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 926-935.
49. Darden T, York D, Pedersen L, (1993) Particle mesh Ewald: An N.log(N) method for Ewald sums in large systems. J Chem Phys 98: 10089-10092.
50. van Gunsteren WF, Berendsen H, (1977) Algorithms for macromolecular dynamics and constraint dynamics. Mol Phys 34: 1311-1327.
51. Tsui V, Case DA, (2000) Molecular dynamics simulations of nucleic acids with a Generalized Born solvation model. J Am Chem Soc 122: 2489-2498.
52. Bashford D, Case DA, (2000) Generalized Born models of macromolecular solvation effects. Annu Rev Phys Chem 51: 129-152.
53. Jayaram B, Sprous D, Beveridge DL, (1998) Solvation free energy of biomacromolecules: Parameters for a modified Generalized Born model consistent with the AMBER force field. J Phys Chem B 102: 9571-9576.
54. Connolly M, (1983) Solvent-accessible surfaces of proteins and nucleic acids. Science 221: 709-713.
55. Sanner MF, Olson AJ, Spehner JC, (1996) Reduced surface: an efficient way to compute molecular surfaces. Biopolymers 38: 305-320.
56. Case DA, (1994) Normal mode analysis of protein dynamics Current Opinion in Structural Biology. 4: 285-290.
57. DeLano W (2002) The PyMOL molecular graphics system. SanCarlos CA, USA: DeLano Scientific.
58. Humphrey W, Dalke A, Schulten K, (1996) VMD-Visual Molecular Dynamics. J Mol Graph 14: 33-38.
59. Massova I, Kollman PA, (1999) Computational Alanine Scanning To Probe Protein-Protein Interactions: A Novel Approach To Evaluate Binding Free Energies. J Am Chem Soc 121: 8133-8143.
60. Jiang W, Roux B, (2010) Free Energy Perturbation Hamiltonian Replica-Exchange Molecular Dynamics (FEP/H-REMD) for Absolute Ligand Binding Free Energy Calculations. J Chem Theory Comput 6: 2559-2565.
61. Hou T, Wang J, Li Y, Wang W, (2011) Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. Journal of Chemical Information & Modeling 51: 69-82.
62. Hayes JM, Archontis G (2011) MM-GB(PB)SA Calculations of Protein-Ligand Binding Free Energies. In: Wang L, editor. J R Soc Interface: InTech. 171-190.
63. Singh N, Warshel A, (2010) Absolute binding free energy calculations: On the accuracy of computational scoring of protein-ligand interactions. Proteins: Structure, Function & Bioinformatics 78: 1705-1723.
64. Faver JC, Benson ML, He X, Roberts BP, Wang B, et al. (2011) Formal Estimation of Errors in Computed Absolute Interaction Energies of Protein-ligand Complexes. J Chem Theory Comput 7: 790-797.
65. Dror RO, Dirks R, Grossman JP, Xu H, Shaw DE, (2012) Biomolecular simulation: a computational microscope for molecular biology. Annu Rev Biophys 41: 429-452.
66. Ng YW, Raghunathan D, Chan PM, Baskaran Y, Smith DJ, et al. (2010) Why an A-loop phospho-mimetic fails to activate PAK1: understanding an inaccessible kinase state by molecular dynamics simulations. Structure 18: 879-890.
67. Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, et al. (2007) Structural insights into the degradation of Mcl-1 induced by BH3 domains Proc Natl Acad Sci U S A. 104: 6217-6222.
68. Lee EF, Smith BJ, Horne WS, Mayer KN, Evangelista M, et al. (2011) Structural Basis of Bcl-x(L) Recognition by a BH3-Mimetic α/β-Peptide Generated by Sequence-Based Design. Chembiochem 12: 2025-2032.
69. Mendes J, Baptista AM, Carrondo MA, Soares CM, (1999) Improved modeling of side-chains in proteins with rotamer-based methods: a flexible rotamer model. Proteins 37: 530-543.
70. Bower MJ, Cohen FE, Dunbrack RL Jr, (1997) Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. J Mol Biol 267: 1268-1282.
71. Harrison RS, Shepherd N, Hoang HN, Ruiz-Gómez G, Hill TA, et al. (2010) Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency. Proc Natl Acad Sci U S A 107: 11686-11691.
72. Abdel-Rahman N, Martinez-Arias A, Blundell TL, (2011) Probing the druggability of protein-protein interactions: targeting the Notch1 receptor ankyrin domain using a fragment-based approach. Biochem Soc Trans 39: 1327-1333.
73. Valkov E, Sharpe T, Marsh M, Greive S, Hyvönen M, (2012) Targeting protein-protein interactions and fragment-based drug discovery. Top Curr Chem 317: 145-179.
74. Sillerud LO, Larson RS, (2005) Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. Curr Protein Pept Sci 6: 151-169.
75. Madhumalar A, Lee HJ, Brown CJ, Lane D, Verma C, (2009) Design of a novel MDM2 binding peptide based on the p53 family. Cell Cycle 8: 2828-2836.
76. Dastidar SG, Lane DP, Verma CS, (2012) Why is F19Ap53 unable to bind MDM2? Simulations suggest crack propagation modulates binding. Cell Cycle 11: 2239-2247.